Cimzia - Beechwood Capital

Drug Profile

ModalityAntibody

RouteSC

Therapy AreaImmunology

Launch2008-04-22

US LOE2024-01-01

Peak Sales Est$2000M

Formulations[{"id":"cimzia-sc","doses":"200mg, 400mg","route":"SC","device":"Pre-filled syringe","setting":"PATI

Companies

UCB (ORIGINATOR)100%

Expert: Tumor necrosis factor alpha inhibitor that binds and neutralizes TNF-α, reducing inflammatory signaling. Cimzia is pegylated for extended half-life.

Everyday: Blocks TNF, a protein that causes inflammation in autoimmune diseases.

Targets: ["TNF"]

Period	Revenue ($M)
2024	$1,650M
Q4 2024	$400M

Indication	Stage	Key Study	Regional Status
Psoriatic arthritis	APPROVED	RAPID-PsA	[{"stage":"APPROVED","region":"US","approval_date":"2013-09-27"},{"stage":"APPRO
Axial spondyloarthritis	APPROVED	RAPID-axSpA	[{"stage":"APPROVED","region":"US","approval_date":"2013-10-18"},{"stage":"APPRO
Crohn's disease	APPROVED	PRECiSE 1/2	[{"stage":"APPROVED","region":"US","approval_date":"2008-04-22"},{"stage":"APPRO
Plaque psoriasis	APPROVED	CIMPASI-1/2	[{"stage":"APPROVED","region":"US","approval_date":"2018-05-28"},{"stage":"APPRO
Rheumatoid arthritis	APPROVED	RAPID 1/2	[{"stage":"APPROVED","region":"US","approval_date":"2009-05-13"},{"stage":"APPRO
Giant cell arteritis	PHASE3	CIARA	[]
Juvenile idiopathic arthritis	APPROVED	PASCAL	[{"stage":"APPROVED","region":"US","approval_date":"2021-12"},{"stage":"APPROVED

Certolizumab pegol, a PEGylated anti-TNF Fab' fragment for rheumatoid arthritis, Crohn's disease, and psoriatic arthritis. Unique structure with no Fc region, reducing certain antibody-mediated effects; only anti-TNF studied in pregnancy.